Neuroimaging biomarkers have shown high potential to map the disease processes in the application to neurodegenerative diseases (NDD), e.g., diffusion tensor imaging (DTI). For DTI, the implementation of a standardized scanning and analysis cascade in clinical trials has potential to be further optimized. Over the last few years, various approaches to improve DTI applications to NDD have been developed. The core issue of this review was to address considerations and limitations of DTI in NDD: we discuss suggestions for improvements of DTI applications to NDD. Based on this technical approach, a set of recommendations was proposed for a standardized DTI scan protocol and an analysis cascade of DTI data pre-and postprocessing and statistical analysis. In summary, considering advantages and limitations of the DTI in NDD we suggest improvements for a standardized framework for a DTI-based protocol to be applied to future imaging studies in NDD, towards the goal to proceed to establish DTI as a biomarker in clinical trials in neurodegeneration.

神经影像生物标志物在神经退行性疾病（NDD）的应用中显示出绘制疾病过程的巨大潜力，例如扩散张量成像（DTI）。对于 DTI 而言，临床试验中标准化扫描和分析级联的实施有可能进一步优化。在过去的几年中，已经开发出了各种将 DTI 应用改进为 NDD 的方法。本次综述的核心问题是解决 DTI 在 NDD 中的考虑因素和局限性：我们讨论了 DTI 应用程序在 NDD 中的改进建议。基于这种技术方法，针对标准化 DTI 扫描协议以及 DTI 数据预处理和后处理以及统计分析的级联分析提出了一系列建议。总之，考虑到 DTI 在 NDD 中的优点和局限性，我们建议改进基于 DTI 的协议的标准化框架，以应用于 NDD 的未来成像研究，以实现将 DTI 作为临床试验中的生物标志物的目标。神经变性。